CSL shares have plunged sharply over the past year, with analysts questioning earnings outlook, valuation, and acquisition ...
CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...
Carlisle Companies Incorporated (NYSE:CSL) is included among the 15 Best Safe Dividend Stocks for 2026. On March 9, JPMorgan raised its price recommendation on Carlisle Companies Incorporated ...
Earnings call CSL reported H1 FY25 revenue of AUD 8.5B (+5% YoY, constant currency) and NPATA of AUD 2.1B (+5%), reaffirming FY25 NPATA guidance of AUD 3.2–3.3B (+10–13%). Behring led with 10% revenue ...
On Monday 15 June 2026, the Chamber of Employees (CSL) announced that it unanimously adopted its opinion on the... }} ...
Good afternoon, everyone, and thank you for joining us on short notice. My name is Mark Dehring, Head of Investor Relations at CSL. The focus of today's call is CSL's leadership transition, and we ...
CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...
While CSL hunts for a permanent successor to Paul McKenzie, Ph.D., his interim replacement, Gordon Naylor, will be “fully empowered by the board,” with the “mandate to implement any changes necessary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results